TheraBionic P1 Device for Patients With Advanced Hepatocellular Carcinoma (HCC) Who Fail First and Second Line Therapy
Barbara Ann Karmanos Cancer Institute
Summary
The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced hepatocellular carcinoma (HCC) who have no standard of care options can affect patients survival. The main questions it aims to answer are: * will the TheraBionic P1 device affect overall survival in advance HCC * the long term safety and tolerability of the TheraBionic P1 device * assessment of how the disease responded to the TheraBionic P1 device
Eligibility
- Age range
- 22+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Patients with advanced hepatocellular carcinoma (HCC) (defined as a liver tumor not eligible for local therapies given the extent of disease or a livor tumor that recurred after local therapy) * Patients who have failed at least two lines of therapy\* or who are no longer eligible for any line of standard therapy or who are intolerant to at least two lines of therapy. * Patients with evaluable disease * Patients must be ≥ 22 years old and must be able to understand and sign an informed consent. * Female patients of childbearing potential and their partners and male patie…
Interventions
- DeviceTheraBionic P1
Amplitude-modulated electromagnetic fields will be self-administered and given continuously to patients in three 60-minute treatments per day, administered in the morning, middle of the day, and in the evening
Locations (6)
- Karmanos Cancer Institute at McLaren Bay RegionBay City, Michigan
- Karmanos Cancer InstituteDetroit, Michigan
- Karmanos Cancer Institute at McLaren FlintFlint, Michigan
- Karmanos Cancer Institute at McLaren Greater LansingLansing, Michigan
- Karmanos Cancer Institute at McLaren Lapeer RegionLapeer, Michigan
- Karmanos Cancer Institute at McLaren Central Michigan, Morey Cancer CenterMount Pleasant, Michigan